Clinical Trial Update: Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

A Phase 2 efficacy study of RX-10100 for major depressive disorder has completed, according to Rexahn Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• RX-10100

Snippet

Sponsor: Rexahn Pharmaceuticals, Inc. | Conditions: Major Depressive Disorder (MDD) | Phase 2 | Status: COMPLETED